Targeted, Non-Systemic Therapies for Gastrointestinal Diseases

thescience

THE SCIENCE

First Wave BioPharma’s product portfolio is built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

LEARN MORE

PIPELINE

First Wave BioPharma’s GI-disease focused programs span multiple clinical indications ranging from complications from cancer treatment to nutritional disorders and diseases brought on by viral infections and immune malfunction.

Disease targets include large patient populations with inflammatory bowel diseases (ulcerative colitis and Crohn’s), digestive disorders (exocrine pancreatic insufficiency in cystic fibrosis patients), and the COVID-19 pandemic (acute and long-haul COVID-related GI infections).

LEARN MORE

thescience
logo ICO

CONTACT

777 Yamato Road
Suite 502
Boca Raton, FL 33431
(561) 589-7020
info@azurrx.com

SOCIAL MEDIA

logo ICO

CONTACT

777 Yamato Road
Suite 502
Boca Raton, FL 33431
(561) 589-7020
info@azurrx.com

SOCIAL MEDIA